Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (1) · Clozaril (Novartis, original brand; 25 mg and 100 mg tablets); FazaClo (orally disintegrating tablets, 12.5/25/100/150/200 mg); Versacloz (oral suspension 50 mg/mL); multiple generics. All clozapine products are subject to the same REMS monitoring requirements. (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1)

2C-x series (1) · Dissociative (1) · Phenethylamine (1) · Psychedelic (1) · Research material (1) · [[:Category:Neuroleptics|Neuroleptic]] (1) · [[:Category:REMS medicines|REMS medicine (mandatory ANC monitoring)]] (1) · [[:Category:Second-generation neuroleptics|Second-generation neuroleptic (atypical)]] (1) · [[:Category:Treatment-resistant schizophrenia medicines|Treatment-resistant schizophrenia medicine]] (1)

5-HT2A partial agonist (1) · NMDA antagonist; fluorinated ketamine analogue (1) · '"`UNIQ--vote-00000049-QINU`"' (1)

None (3)

None (2) · 12.5 mg PO once or twice daily. Titrate gradually: 25-50 mg/day increments every 1-2 days as tolerated. Target dose 300-450 mg/day in divided doses (BID or TID). Most patients stabilize between 200-600 mg/day. Therapeutic plasma level guide: target trough clozapine ≥350 ng/mL. (1)

None (2) · Clozaril 25 mg and 100 mg tablets; FazaClo orally disintegrating tablets (12.5/25/100/150/200 mg); Versacloz oral suspension 50 mg/mL. All brands subject to identical REMS ANC monitoring requirements. Generic tablets widely available. (1)

None (2) · 900 mg/day (split into BID or TID dosing). Clinical practice rarely exceeds 600 mg/day; seizure risk increases substantially above 600 mg/day and requires consideration of prophylactic anticonvulsant.'"`UNIQ--ref-0000004A-QINU`"' (1)

None (1) · insufflated (1) · Oral (1) · Oral only. No parenteral formulation (a major limitation in acute agitation requiring rapid tranquilization). (1) · PR (1)

None (1) · 45-75 min (oral) (1) · Oral peak plasma 2.5 hours. Clinical antipsychotic response typically emerges over weeks with continued titration; full response assessment requires 3-6 months at adequate therapeutic levels. (1)

None (1) · 4-8 h (1) · Due to the half-life of 12 hours (wide range), dosing is BID or TID. Once-daily dosing produces higher peak/trough fluctuations and is generally not used except for a single end-of-day dose in stable patients. (1)

None (2) · Not well characterized (1)

None (1) · Approximately 50-60% (oral; subject to first-pass metabolism); food does not significantly affect absorption.'"`UNIQ--ref-0000004C-QINU`"' (1) · Not well characterized (1)

None (2) · Not established (1)

None (2) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)